Introduction
Carcinoembryonic antigen (CEA) is a non-specific serum biomarker that is elevated in various malignancies such as colorectal cancer, medullary thyroid cancer, breast cancer, mucinous ovarian cancer, etc. It was first detected in colon cancer cells by Freedman and Goldand eventually was found in various other epithelial cells in thestomach, tongue, esophagus, cervix, and prostate.[1]
It is a glycoprotein with a molecular weight of 200 kDa and is normally derived from embryonic endodermal epithelium in the fetus, controlled by fetal oncogenes. It usually disappears from serum after birth; however, small quantities of CEA may remain in colon tissue. CEA and related genes (29 of which 18 are normally expressed) constitute the CEA family in human beings and are clustered on chromosome 19q13.2.[2]
Since it is associated with various types of malignant and nonmalignant medical conditions (Table 1), elevated serum CEA is not a definitive marker of a particular site ofcancer origin.[3] Therefore, it is not recommended for routine screening or diagnosis of cancers by itself. CEA is currently being studied as a target for various cancer-directed therapies.[4][5]
Table: 1 Malignant and nonmalignant conditions associated with elevated CEA
Table
Malignant Conditions Nonmalignant Conditions
Pathophysiology
CEA belongs to the immunoglobulin family called CEA-related cell adhesion molecules (CEACaMs). CEAis closely associated with various functions of endothelial cells, including adhesion, proliferation, and migration of cells both in vivo and in vitro.[6]It is present on the endoluminal side of the cell membrane of normal cells and is thought to inhibit apoptosis and hence is involved in tumor pathogenesis. Although CEA is predominantly associated with gastrointestinal tumors, literature shows its close correlation with breast, lung, ovarian, mucinous adenocarcinomas of the cervix and thyroid cancers.
Specimen Requirements and Procedure
The test for CEA measurement is usually conducted on a blood sample collected by the health care personnel/phlebotomist. A small quantity of the blood (3to 5 cc) is collected in a vial and sent to the laboratory to estimate the CEA Level. The risks associated with such a procedure are minimal, including needle site pain/stinging, bruising, bleeding, or infections. The procedure takes less than five minutes and does not need specific requirements, such as fasting. Occasionally, a CEA test is performed on other bodily fluids such as pleural fluid, peritoneal fluid, or rarely cerebrospinal fluid.
Testing Procedures
A large number of commercially available products utilize different technologies such as sandwiched enzyme-linked immunosorbent assay (ELISA), immunonephelometry, chemiluminometric immunoassay (CLIA), immunomagnetic reduction (IMR), etc. CEA levels can fluctuate based on the type of testing procedure utilized. Therefore,discordant serial CEA levels need to be carefully correlated with differences in testing procedures. Using monoclonal antibodies directed against the six reactive isotopes of CEA in specific assays could result in erroneous findings amongst those patients who have been previously treated with monoclonal antibodies.[7]
Interfering Factors
CEA is predominantly metabolized in the liver. Therefore, hepatic and biliary dysfunction can be associated with elevated levels causing false positives. Because of high first-pass hepatic metabolism, significantly elevated levels correspond to either CEA-producing tumors or metastases outside portal venous drainage territory. Tumor differentiation can also affect the CEA levels, with higher CEA levels seen in well-differentiated cancers.[8][9]Amongst benign conditions that affect CEA levels, smoking is one of the common causes. It has been established that smoking increases CEA levels.[10][11]
Results, Reporting, and Critical Findings
Ranges
In healthy, non-smoking adults, CEA is considered within normal limits at a level of <=3.0 µg/L. Smokers may have elevated CEA, and therefore it is considered within normal limits at a level of <5 µg/L. Pre-treatment serum CEA levels of greater than five µg/L but less than ten µg/L suggests localized disease and a low likelihood of recurrence, hence a favorable prognosis. A serumlevel of >10 µg/L indicates a higher likelihood of recurrence and poor prognosis.
Serum titers of >20 µg/L are usually associated with metastatic disease in breast and colon cancers. However, given the variability in CEA expression or secretion, values <2.5 µg/L do not necessarily rule out primary, recurrent or metastatic cancers, either. For colorectal cancers, a CEA threshold of 2.5µg/L carries a sensitivity of 82% and a specificity of 80%, while a threshold of 10 µg/L carries a sensitivity of 68% and specificity of 97%.[12]
Advantages
Serum-based CEA testing is a cost-effective surveillance method in various cancers and is part of various national and international surveillance guidelines. It is also an equally important tool to assess ongoing response to palliative treatments in metastatic cancers, along with imaging studies. It isa very easy and widely available tool, even in a community setting.
Drawbacks
Due to low sensitivity and specificity, it cannot be used as a screening test to detect malignancies. Although used for detecting recurrence of cancer after primary surgical and adjuvant treatments, a single value (one-time measurement) is inadequate due to low sensitivity (high false-positive rate), and serial measurements (trend) are essential. Raising CEA cut-off (>10 µg/L) and combining it with other modalities such as CT scans of chest, abdomen, and pelvis at 12 months intervals is recommended instead of using it as a sole test for monitoring recurrence of colorectal cancer.
People exposed to certain animal antigens may develop antibodies to CEA that might affect CEA levels and lead to unreliable results. Smokers are highly likely to get false-positive results; therefore, the test is unreliable in active smokers. It is not recommended to use CEA for follow-up in active smokers with colon cancer after primary treatment.
Clinical Significance
CEA in Colorectal Cancer Diagnosis and Post-Treatment Surveillance to Monitor Recurrence/Residual Tumor
CEA is a strong prognostic biomarker in patients with colorectal cancer who underwent surgical resection and adjuvant chemotherapy.[13]Elevated CEA level of >5 µg/L at the time of new diagnosis of colorectal cancer is associated with poor prognosis.[14]However, normalization of elevated CEA levels after surgery is not associated with a poor prognosis. Hence routine assessment of CEA before surgical treatment is not indicated, and usually, post-operative detection is more useful in detecting recurrence within the first year of surgery and prognostication.
Follow-up with CEA level in patients with colorectal cancers after primary treatment was found effective in detecting cancer recurrences that can be treated with curative intent in the follow-up after colorectal surgery (FACS) trial.[15]The national guidelines in North America and Europe also endorse measurement of CEA during post-operative follow-up in colorectal cancer.[16][17]
Serial monitoring of CEA is recommended before initiation of treatment and after that every three months during active treatment and during active surveillance to assess the response to resection and systemic therapy (chemotherapy/radiotherapy) in colorectal cancer.[18]
In colorectal cancer, serum CEA normalizes in 6 weeks after the resection of the tumor. Therefore, persistently elevated CEA levels may indicate residual tumor due to incomplete resection or recurrence of the tumor. Restaging malignancy should be considered if there is persistently rising CEA above baseline, potentially suggesting cancer progression. CEA level should not be checked too early, i.e., 4to 6 wks. of starting a new therapy as some chemotherapeutic agents may elevate CEA falsely.[19][20]The increasing level of CEA precedes the clinical recurrence, leading to early suspicion/detection of recurrence.
As endorsed by the American Society of Clinical Oncology guidelines (2006 and 2013 updates), for patients with stage II and stage III colorectal cancer who are candidates for surgery or chemotherapy, post-operative/post-treatment CEA measurement should be done every three months for at least two years along with annual CT scans, followed by every six months for five years.[21]
The sensitivity and specificity of serial measurement of CEA in detecting recurrent colorectal cancer are approximately 80% and 70%, respectively.[22]It has the advantage of providing a lead time of about five months compared to other diagnostic methods for detecting recurrence. Early detection increases the chance of surgical cure by timely resection of recurrent tumors.
Post Resection Detection of Liver Metastasis/Oligometastases
CEA measurement is the most sensitive detector of liver metastasis from colorectal cancers that can be resected surgically.[23]There is evidence that colon cancer patients with liver metastasis with preoperative CEA less than or equal to 30 µg/L have more likelihood of having resectable metastatic lesions and hence more prolonged survival.[24]When monitoredalong with CT scans, CEA has proven to detect the metastasis in surgically curable stage than either modality alone.
CEA in Medullary Carcinoma of the Thyroid
According to the revised guidelines of the American Thyroid Association for the management of medullary thyroid carcinoma, CEA is not a specific biomarker for medullary carcinoma. However, measuring CEA levels is very helpful in assessing the disease progression and post thyroidectomy monitoring. According to Chen et al., the North America Society for Neuroendocrine Tumors (NANETS) guidelines, preoperative levels above 30µg/L indicate the extra-thyroid spread of the disease. In contrast, levels greater than 100 µg/L are associated with invasive disease, including lymph node involvement and distant metastasis.[25]
It is recommended to plan surgical treatment with total thyroidectomy, central cervical lymph node dissection, and unilateral lateral cervical lymph node dissection when CEA levels are greater than 30 µg/L. Pre-targeted radioimmunotherapy (radiolabeled monoclonal antibodies against CEA) is a promising treatment modality in treating medullary carcinoma of the thyroid.Patients with persistent CEA levels after colon cancer surgery and a negative diagnostic workup for metastatic disease should steer the diagnostic workup towards medullary carcinoma of the thyroid, including calcitonin measurement and neck ultrasound.[26]
CEA in Ascitic Fluid
CEA levels are proven to be of some value in cases where ascitic fluid cytology is inconclusive. Serum levels greater than 5 µg/L aresuggestive ofcarcinoma. However,higher values were common in cancers with peritoneal involvement with a sensitivity of 51 % and specificity of 97% for carcinomatosis (p <0.01).[27]
CEA in Pleural Fluid
An elevated CEA level in a patient with pleural fluid and negative cytology precludes more invasive modalities such as VATS guided biopsy to rule out malignant etiology. In contrast, lower CEA levels may support a close follow-up.[28]
CEA in Non-Small-Cell Lung Cancer (NSCLC)
Due to limited preoperative imaging sensitivity, 30% of patients with stage I NSCLC have positive N2-N3 nodes at the time of diagnosis. Preoperative CEA levels help identify patients with advanced disease that might be missed on imaging. Higher CEA levels correlate with advanced stage, nodal metastasis, and poor survival. It potentially identifies the patient population who would benefit from invasive mediastinal lymph node staging by mediastinoscopy or endoscopic ultrasound and benefit from neoadjuvant chemotherapy or chemoradiotherapy than upfront surgery.[29][30]
CEA in Breast Cancer
Currently, routine use of CEA in screening for breast cancer is not recommended as per ASCO due to limited sensitivity and specificity. However, in addition to CA 15-3 and CA 27.29, CEA and diagnostic imaging can be used to monitor patients with metastatic disease receiving active therapy.[31]
References
- 1.
Téllez-Avila FI, García-Osogobio SM. [The carcinoembryonic antigen: apropos of an old friend]. Rev Invest Clin. 2005 Nov-Dec;57(6):814-9. [PubMed: 16708907]
- 2.
Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999 Apr;9(2):67-81. [PubMed: 10202129]
- 3.
Wang H, Meng AM, Li SH, Zhou XL. A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer. Mol Med Rep. 2017 Jul;16(1):625-630. [PMC free article: PMC5482067] [PubMed: 28586008]
- 4.
Lázaro-Gorines R, Ruiz-de-la-Herrán J, Navarro R, Sanz L, Álvarez-Vallina L, Martínez-Del-Pozo A, Gavilanes JG, Lacadena J. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts. Sci Rep. 2019 Aug 12;9(1):11680. [PMC free article: PMC6690998] [PubMed: 31406218]
- 5.
Shinmi D, Nakano R, Mitamura K, Suzuki-Imaizumi M, Iwano J, Isoda Y, Enokizono J, Shiraishi Y, Arakawa E, Tomizuka K, Masuda K. Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. Cancer Med. 2017 Apr;6(4):798-808. [PMC free article: PMC5387159] [PubMed: 28211613]
- 6.
Zi-Yang Y, Kaixun Z, Dongling L, Zhou Y, Chengbin Z, Jimei C, Caojin Z. Carcinoembryonic antigen levels are increased with pulmonary output in pulmonary hypertension due to congenital heart disease. J Int Med Res. 2020 Nov;48(11):300060520964378. [PMC free article: PMC7683927] [PubMed: 33203284]
- 7.
Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R, Bormer O, Buchegger F, Mach JP, Burtin P. Antigenic sites in carcinoembryonic antigen. Cancer Res. 1989 Sep 01;49(17):4852-8. [PubMed: 2474375]
- 8.
Siregar GA, Sibarani H. Comparison of Carcinoembryonic Antigen Levels Among Degree of Differentiation and Colorectal Cancer's Location in Medan. Open Access Maced J Med Sci. 2019 Oct 30;7(20):3447-3450. [PMC free article: PMC6980806] [PubMed: 32002071]
- 9.
Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, Zamcheck N. Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981 Aug;71(2):246-53. [PubMed: 6167166]
- 10.
Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA. 1976 May 03;235(18):1975-9. [PubMed: 56468]
- 11.
f*ckuda I, Yamakado M, Kiyose H. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst. 1998 Apr;22(2):89-93. [PubMed: 9571515]
- 12.
Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, Perera R, Primrose JN, Mant D. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015 Dec 10;2015(12):CD011134. [PMC free article: PMC7092609] [PubMed: 26661580]
- 13.
Ozawa T, Matsuda K, Ishihara S, f*ckushima Y, Shimada R, Hayama T, Nozawa K, Hashiguchi Y. The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer. J Surg Oncol. 2021 Jul;124(1):97-105. [PubMed: 33848373]
- 14.
Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash GM, Guillem JG, Paty PB, Garcia-Aguilar J, Gonen M, Weiser MR. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol. 2018 Mar 01;4(3):309-315. [PMC free article: PMC5885834] [PubMed: 29270608]
- 15.
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D., FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014 Jan 15;311(3):263-70. [PubMed: 24430319]
- 16.
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 01;11(2):141-52; quiz 152. [PubMed: 23411381]
- 17.
Addendum to clinical guideline 131, Colorectal cancer. National Institute for Health and Care Excellence (NICE); London: Dec, 2014. [PubMed: 31815386]
- 18.
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC., ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20;24(33):5313-27. [PubMed: 17060676]
- 19.
Sørbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol. 2003 Dec 01;21(23):4466-7. [PubMed: 14645446]
- 20.
Sørbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol. 2004;43(5):495-8. [PubMed: 15360055]
- 21.
Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB., American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsem*nt. J Clin Oncol. 2013 Dec 10;31(35):4465-70. [PubMed: 24220554]
- 22.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001 Apr;47(4):624-30. [PubMed: 11274010]
- 23.
Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980 Apr;23(3):141-4. [PubMed: 7379666]
- 24.
Bakalakos EA, Burak WE, Young DC, Martin EW. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg. 1999 Jan;177(1):2-6. [PubMed: 10037299]
- 25.
Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K., North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010 Aug;39(6):775-83. [PMC free article: PMC3419007] [PubMed: 20664475]
- 26.
Nien FJ, Chang TC. Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy. J Formos Med Assoc. 2015 Sep;114(9):793-4. [PubMed: 23906686]
- 27.
Gulyás M, Kaposi AD, Elek G, Szollár LG, Hjerpe A. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol. 2001 Nov;54(11):831-5. [PMC free article: PMC1731306] [PubMed: 11684715]
- 28.
Hackner K, Errhalt P, Handzhiev S. Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion. Ther Adv Med Oncol. 2019;11:1758835919850341. [PMC free article: PMC6535745] [PubMed: 31205509]
- 29.
Kuo YS, Zheng MY, Huang MF, Miao CC, Yang LH, Huang TW, Chou YT. Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression. Sci Rep. 2020 Feb 07;10(1):2066. [PMC free article: PMC7005848] [PubMed: 32034239]
- 30.
Nasralla A, Lee J, Dang J, Turner S. Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: a systematic review and meta-analysis. J Cardiothorac Surg. 2020 Oct 15;15(1):318. [PMC free article: PMC7565320] [PubMed: 33059696]
- 31.
Zhao W, Li X, Wang W, Chen B, Wang L, Zhang N, Wang Z, Yang Q. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer. Dis Markers. 2021;2021:5529106. [PMC free article: PMC8492280] [PubMed: 34621407]
Disclosure: Vijaya Kankanala declares no relevant financial relationships with ineligible companies.
Disclosure: Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.
